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In 1616, Sir William Harvey was the first person to describe the 
importance of right ventricular function.1 However, the right ventricle 
(RV) has received little attention in the past, with cardiology dealing 
mostly with the diseases of the left ventricle (LV) and their potential 
treatment. Since the early 1950s, however, the prognostic significance 
of RV function has been recognised in several conditions, primarily 
those involving the LV (e.g. chronic LV failure), the lungs and their 
vascular bed (e.g. pulmonary embolism, chronic pulmonary disease 
and pulmonary arterial hypertension) or the right-sided chambers (e.g. 
RV infarction, RV cardiomyopathies and congenital heart diseases). 
Recent advances in imaging techniques have created new 
opportunities to study RV anatomy, physiology and pathophysiology, 
and contemporary research efforts have opened the doors to new 
treatment possibilities.2,3 Nevertheless, the treatment of RV failure 
remains challenging. This article aims to provide an overview of the 
pathophysiology, diagnosis and treatment of RV failure.
Anatomical and Physiological Particularities of 
the Right Ventricle 
The RV is a unique chamber with distinct anatomy and physiology.4 It 
is coupled to systemic venous return and the pulmonary circulation. 
Since the pressure in the pulmonary circulation is generally much lower 
than it is in the systemic circulation, less muscle power is needed (a 
quarter of the LV stroke work).5 Therefore, the RV needs fewer muscle 
fibres and is much thinner than the LV, having about one-third of the 
thickness. Furthermore, venous return fluctuates, so the RV is much 
more compliant and is slightly larger (approximately 10–15%) than the 
LV, which allows it to accommodate large variations in venous return 
without altering end-diastolic pressure. Each systolic contraction leads 
to a primarily longitudinal shortening, whereas LV contraction is more 
circumferential.6 Notably, both ventricles share the septum, and up to 
40% of the RV systolic function is dependent on septal contraction.7 
During exercise, a 30–50% decrease in predicted VO2 max can be seen 
in healthy Fontan patients, which indirectly highlights the critical role 
of the RV for maintaining cardiac output.8
The RV consists of the inlet with the tricuspid valve, chordae tendineae, 
at least three papillary muscles, the trabeculated apex and the 
infundibulum (a muscular structure supporting the pulmonary valve 
leaflets). For imaging analysis, the RV is divided into four segments: the 
infundibulum, and the anterior, lateral and inferior wall.9 
The right coronary artery, at least in most individuals, perfuses the 
RV free wall and the posterior third of the interventricular septum. 
The left anterior descending artery perfuses the apex and the 
anterior part of the septum. Unlike the LV, RV perfusion occurs 
both in systole and diastole and the collateral vessels of the RV are 
denser than those of the LV. However, because of its thinner wall and 
higher dependence on coronary perfusion pressure, RV perfusion is 
more vulnerable to an increase in RV size (intramural pressure) and 
systemic hypotension.10
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One of the main characteristics of the RV is its greater sensitivity to 
changes in afterload. Brisk increases in afterload are poorly tolerated 
and lead to RV dilatation to preserve stroke volume. One seminal 
work highlighted the response of the right and left ventricle to 
experimental increases in afterload. While an increase on the left side 
leads to only a slight decrease in stroke volume, the same increase in 
the RV results in a marked fall in stroke volume (Figure 1). 
A further important characteristic is ventricular interdependence. 
Excessive RV volume loading is constrained by the pericardium 
and therefore results in compression and D-shaping of the LV. 
Volume overload in the RV therefore indirectly leads to a decrease in 
LV stroke volume. 
The anatomical and functional particularities of the RV have been 
reviewed in detail elsewhere.4
Causes and Pathophysiology of Right Ventricular 
Failure
The normal RV function is an interplay between preload, contractility, 
afterload, ventricular interdependence and heart rhythm. Most cases 
of RV failure follow existing or new-onset cardiac or pulmonary 
diseases or a combination of both, which may increase RV afterload, 
reduce RV contractility, alter RV preload or ventricular interdependence 
or cause-related arrhythmias (Table 1 and Figure 2). To understand RV 
failure, it is crucial to assess these five components.
Right Ventricular Failure in Cardiac Disease
Increased afterload is the main pathophysiologic mechanism for RV 
failure of both pulmonary and cardiac origin. Indeed, the prevalence 
of left ventricular systolic or diastolic dysfunction and (post-capillary) 
pulmonary hypertension in patients with RV failure is particularly 
high, which corroborates the concept that the majority of RV failure 
is secondary to left-sided cardiac or pulmonary (vascular) diseases.11 
Increased afterload is also a main cause of ventricular failure in 
patients with systemic RV (e.g. patients after atrial switch repair 
for complete transposition of the great arteries, with congenitally 
corrected transposition of the great arteries or after Fontan palliation) 
or with obstruction of the RV outflow tract. In patients with other forms 
of adult congenital heart disease (e.g. atrial septal defect with relevant 
left-to-right shunt or severe pulmonary regurgitation in repaired Fallot’s 
tetralogy), chronic volume overload may induce RV dilation and failure. 
Cardiac diseases involving the right heart may primarily reduce RV 
contractility or, through reduced cardiac output, reduce RV preload, 
contributing to RV failure. 
Virtually all myocardial diseases involving the left heart may affect the 
RV. These include myocardial ischaemia/infarction, myocarditis/septic 
cardiomyopathy, takotsubo cardiomyopathy, dilated cardiomyopathy, 
hypertrophic cardiomyopathy, cardiac amyloidosis and Chagas 
disease. Cardiomyopathies with primary involvement of the RV include 
arrhythmogenic RV cardiomyopathy (characterised by fibrofatty 
replacement of the RV myocardium), Uhl’s anomaly (which involves 
aplasia or hypoplasia of most of the RV myocardium), and Ebstein’s 
anomaly (defined as apical displacement of the septal and posterior 
tricuspid leaflets, which induces severe tricuspid regurgitation).
Pericardial diseases may alter RV preload and ventricular 
interdependence, while arrhythmia may aggravate RV dysfunction. 
Notably, iatrogenic RV failure through excessive volume loading or 
mechanical ventilation is frequently seen in critically ill patients, while 
ischaemic RV injury is sometimes seen after cardiac surgery. Finally, 
RV failure may be exacerbated in patients undergoing left ventricular 
assist device (LVAD) implantation, causing high morbidity and mortality 
and requiring temporary RV support. This topic has been reviewed 
extensively elsewhere.12
Right Ventricular Failure in Pulmonary Disease
RV failure as a consequence of lung disease is commonly described as 
cor pulmonale. These changes might occur dramatically – for example 
in fulminant pulmonary embolism – or might be due to longstanding 
respiratory disorders that result in chronic alterations of RV structure 
and function.
In the context of acute respiratory insufficiency in a previously healthy 
individual, impending RV failure is almost exclusively seen with 
massive pulmonary embolism. Of note, the elevation of pulmonary 
pressure following acute pulmonary embolism is observed only 
when more than half of the pulmonary vasculature is obstructed by 
thrombotic material.13 This is because distension and recruitment of 
additional pulmonary capillaries might decrease vascular resistance 
and compensate for circulatory changes.14 When thrombotic occlusion 
extends to more than 50% of the lung vessels and, in turn, pressure 
elevation occurs, the unconditioned RV can overcome a mean 
pulmonary arterial pressure of up to 40 mmHg.15 A higher afterload 
results in acute RV failure and obstructive shock. Conversely, if there is 
acute pulmonary embolism and the RV is exposed to higher pressure 
values and can tolerate it, a pre-existing elevation of pulmonary 
pressure (i.e. the presence of pulmonary hypertension) with an 
antecedent adaption of the RV must be assumed. 
Many chronic lung diseases affect the pulmonary circulation 
and the right heart, but chronic obstructive pulmonary disease 
Right ventriclar stroke volume decreases rapidly when afterload is increased, in contrast to 
left ventricular stroke volume which is maintained against an augmented afterload.  
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Figure 1: Effect of Increasing Afterload on Stroke Volume 
of the Right and Left Ventricles
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(COPD) is the most prevalent cause of respiratory insufficiency 
and cor pulmonale. COPD increases RV afterload by several 
mechanisms, including rarefaction of the vascular bed, hypercapnia 
and acidosis, pulmonary hyperinflation, airway resistance, 
endothelial dysfunction and hypoxia.16 Of these factors, hypoxia 
is arguably the most prominent driver of pulmonary hypertension 
and subsequent RV failure. Hypoxic pulmonary vasoconstriction 
(the Euler-Liljestrand effect) results in pulmonary pressure 
elevation and, when persistent, vascular remodelling and fixed 
pulmonary hypertension.17 
The presence of pulmonary hypertension has long been considered as 
the conditio sine qua non for the development of a cor pulmonale.18 
Recent data have challenged this assumption and suggested 
that, in patients with lung disease, structural alterations in cardiac 
myocytes predate the development of clinically manifested pulmonary 
hypertension.19 As such, cor pulmonale and failing RV syndrome in lung 
disease may be part of a disease spectrum rather than being distinct 
entities.20 With its impact on RV function, pulmonary hypertension – 
more than airflow limitation – is the strongest predictor of an adverse 
outcome and mortality in patients with lung disease. 
Diagnosis of Right Ventricular Failure
Clinical Signs
The clinical signs of RV failure are mainly determined by backward 
failure causing systemic congestion. In severe forms, the right heart 
dilates and, through interventricular dependence, can compromise 
LV filling, reducing LV performance and causing forward failure 
(i.e. hypotension and hypoperfusion). Backward failure presents as 
elevated central venous pressure with distension of the jugular veins 
and may lead to organ dysfunction and peripheral oedema.21 
The association between systemic congestion and renal, hepatic 
and gastrointestinal function in heart failure has been extensively 
studied.22 Elevated central venous pressure is the main determinant of 
impaired kidney function in acute heart failure.23,24 Hepatic dysfunction 
is also highly prevalent in acute heart failure; systemic congestion 
frequently presents with a cholestatic pattern, while hypoperfusion 
typically induces a sharp increase in circulating transaminases.25 
Finally, systemic congestion may alter abdominal function, including 
reduced intestinal absorption and impaired intestinal barrier.26
ECG
The ECG in chronic RV failure often shows right axis deviation as a 
consequence of RV hypertrophy. Other ECG criteria are RS-ratio in 
lead V5 or V6 ≤1, SV5 or V 6≥7 mm, P-pulmonale or a combination of 
these. While the sensitivity of those criteria is quite low (18–43%), the 
specificity ranges from 83% to 95%.27 RV strain is sometimes seen in 
massive pulmonary embolism as an initial S deflection in I, an initial 
Q-deflection in III and T-Inversions in III (high specificity, low sensitivity), 
as well as in V1–V4.28 Moreover, RV failure is often accompanied by 
atrial flutter or AF. 
Imaging
The primary working tool for imaging the (failing) RV is echocardiography. 
It should be emphasised that a comprehensive assessment of the 
anatomy and function of the right heart should include left heart 
function, pulmonary haemodynamics, the tricuspid valve and the right 
atrium. In most patients, transthoracic assessment by echocardiography 
is sufficient to describe RV morphology and function adequately. 
However, because of the RV’s complex shape, echocardiography can 
only partially visualise it. Careful attention should be paid in obtaining 
an RV focused view from the apical four-chamber view with rotation of 
the transducer to obtain the maximal plane.8 Other views, such as the 
short axis and RVOT view, add anatomical and functional information. 
The measurements of RV function that are most frequently used and 
easiest to perform are fractional area change, tricuspid annular plane 
systolic excursion (TAPSE), pulsed tissue Doppler S’ or RV index of 
myocardial performance (RIMP). However, RIMP is rarely used and 
cumbersome to calculate.29,30 
Altered rhythm
Increased afterload
Abnormal preload
Altered interdependence
Reduced contractility
RA
RV
Lungs
LA
LV
Figure 2: Mechanisms of Right Ventricular Dysfunction
Table 1: Mechanisms and Causes of Right Ventricular 
Failure
Mechanism Cause
Increased afterload LV backward failure (pulmonary hypertension 
associated with left-sided heart disease)
Pulmonary embolism, chronic thromboembolic 
pulmonary hypertension
Pulmonary artery hypertension
(Exacerbated) chronic pulmonary disease
Acute lung injury/acute respiratory distress 
syndrome
Sleep-related breathing disorders, obesity-
hypoventilation syndrome
Mechanical ventilation
(Repaired) congenital heart disease with systemic 
RV or RV outflow obstruction
Reduced contractility RV ischaemia/RV infarction
RV injury, systemic inflammatory response (SIRS)
Myocarditis
Cardiomyopathies (e.g. dilated cardiomyopathy or 
hypertrophic cardiomyopathy)
Arrhythmogenic RV cardiomyopathy, Uhl’s anomaly
Abnormal preload Hypo- or hypervolaemia
LV forward failure
Pericardial tamponade
Mechanical ventilation
Chronic left-to-right shunt
Altered interdependence Pericardial tamponade
Pericardial disease
Septal shift
Altered rhythm Bradyarrhythmia
Tacharrhythmia
LV = left ventricle; RV = right ventricle.
LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle.
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Guidelines recommend a comprehensive approach and using a 
combination of these measurements to assess RV function as none 
of them alone can adequately describe RV function in different 
scenarios.29 Moreover, these measurements are all somewhat load 
dependent and therefore subject to physiologic variation. Newer 
imaging techniques, such as 3D-echocardiography and strain imaging, 
have proven to be useful and accurate imaging modalities but have 
limitations because they depend on good image quality and lack 
validation in larger cohorts.31,32
Cardiac MRI has become the standard reference method for right 
heart acquisition as it is capable of visualising anatomy, quantifying 
function and calculating flow. In addition, it is useful in cases 
where image quality by echocardiography is limited. Moreover, it 
can provide advanced imaging with tissue characterisation, which 
is useful in different cardiomyopathies, such as arrhythmogenic RV 
cardiomyopathy, storage disease and cardiac tumours. Limitations are 
mainly due to the thinness of the RV wall, which can make it challenging 
to differentiate it from surrounding tissues.9 In addition, pacemakers or 
pacemaker leads may interfere with image acquisition during MRI and 
lead to artefacts that impair visualisation of the RV walls. 
Cardiac CT and nuclear imaging play a minor role although cardiac 
CT can help to visualise anatomy when MRI is not feasible. There are 
concerns regarding radiation exposure from both nuclear imaging and 
dynamic imaging by CT angiography.
Medical Treatment of Acute Right Ventricular 
Failure
The Heart Failure Association and the Working Group on Pulmonary 
Circulation and Right Ventricular Function of the European Society 
of Cardiology recently published a comprehensive statement on the 
management of acute RV failure.33 The triage and initial evaluation of 
patients presenting with acute RV failure aim to assess clinical severity 
and identify the cause(s) of RV failure, with a focus on those requiring 
specific treatment. Management of acute RV failure requires not only 
an understanding of the anatomical and physiological particularities 
of the RV but also rapid identification and treatment of the underlying 
causes and related pathophysiological disorders (see above). 
In this context, echocardiography and other imaging modalities are 
frequently essential to identify the cause of RV failure and guide 
treatment. In patients presenting with severe RV failure, rapid initiation 
of treatment to restore haemodynamic stability is essential to prevent 
significant, potentially irreversible end-organ damage. 
Acute treatment consists of four elements: volume optimisation; 
restoration of perfusion pressure; improvement of myocardial 
contractility; and advanced options (Figure 3). 
Volume Optimisation
A common misconception is that RV failure should consistently be 
treated with volume supplementation. Conversely, while the RV might 
physiologically be able to accommodate large variations in preload 
and some patients with RV failure are preload dependent, a large 
proportion of RV failure is caused, associated with or aggravated by 
RV volume overload. In such cases, volume loading has the potential 
to overdistend the RV and thereby increase wall tension, decrease 
contractility, aggravate tricuspid regurgitation, increase ventricular 
interdependence, impair LV filling and, ultimately, reduce systemic 
cardiac output and exacerbate organ dysfunction.24,33,34 In patients with 
RV failure and signs of venous congestion, diuretics are often the first 
option to optimise volume status. 
Notably, in patients with massive renal congestion due to severe RV 
dysfunction and/or severe tricuspid regurgitation, sufficient renal 
perfusion pressure (i.e. mean arterial pressure minus central venous 
pressure) and an adequate diuretics plasma concentration are crucial 
to achieving the desired effect. Furthermore, since most of the 
effect of IV loop diuretics occurs within the first hours – with sodium 
excretion returning to baseline within 6–8 hours – 3–4 daily doses or 
continuous infusion are required to maintain the decongestive effect.35 
In the context of RV failure, early evaluation of the diuretic response 
(by measuring urine output or post-diuretic spot urinary sodium 
content) to identify patients with an inadequate diuretic response is 
even more important than it is in other forms of acute heart failure. If 
decongestion is insufficient, rapid intensification of loop diuretic dose, 
starting a sequential nephron blockade (combining diuretics with a 
different mode of action) or the use of renal replacement therapy/
ultrafiltration should be considered. 
In the absence of elevated filling pressure, cautious volume loading 
guided by central venous pressure monitoring may be appropriate.33
Restoration of Perfusion Pressure
Vasopressors are primarily indicated to restore arterial blood pressure 
and improve organ perfusion. Noradrenaline can restore systemic 
haemodynamics without increasing RV afterload (i.e. there is no 
effect on pulmonary vascular resistance).36 Restoration of coronary 
perfusion pressure by vasopressors is a mainstay of therapy since 
the failing RV dealing with volume and/or pressure overload is 
particularly susceptible to ischaemic injury. Furthermore, vasopressors 
restore cerebral, renal and hepato-splanchnic perfusion pressures. 
Clinical data suggest that targeting a mean arterial pressure (MAP) 
of 65 mmHg may be reasonable. However, MAP alone should not be 
AMI = acute MI; BNP = B-type natriuretic peptide; MAP mean arterial pressure; NO = nitric 
oxide; PCI = percutaneous coronary intervention; PDE3i = phosphodiesterase-3 inhibitor; 
PE = pulmonary embolism; TTE = transthoracic echocardiography. Adapted from Harjola  
et al. 2016.33
Conrm diagnosis
Assess severity
Clinical parameters
Lab values (BNP, troponin, lactate)
lmaging (TTE)
Identify and treat the cause
Optimise volume status
Restore perfusion pressure
Improve myocardial contractility
Consider advanced options
ECG, imaging (TTE, CT scan)
PCI for AMI, reperfusion for PE
Volume bolus if preload-dependent
Diuretics in case of congestion
Add noradrenaline 
 MAP >65 mmHg, personalise target
Add positive inotropic drug
(levosimendan, dobutamine, PDE3i)
Inhaled NO, inhaled prostacyclins
Mechanical circulatory support
Figure 3: Algorithm for the Treatment of Acute Right 
Ventricular Failure 
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used as a surrogate measure of organ perfusion pressure, especially 
in patients with RV failure and severe tricuspid regurgitation with 
massively elevated central venous pressure. Organ-specific perfusion 
pressure targets include 50–70 mmHg for the brain, 65 mmHg for renal 
perfusion and >50 mmHg for hepato-splanchnic flow.37 Therefore, the 
MAP targets should be personalised based on the measures of organ 
function and tissue perfusion.
Improvement of Myocardial Contractility
Dobutamine, levosimendan and phosphodiesterase III inhibitors 
improve contractility and increase cardiac output and are indicated 
in patients with severe RV failure causing cardiogenic shock despite 
treatment with vasopressors.33 Levosimendan and phosphodiesterase 
III inhibitors may favourably affect the ventricular-arterial coupling 
by combining RV inotropy and pulmonary vasodilation and might 
be preferentially indicated in patients with pulmonary hypertension 
caused by left heart disease.24,38 The use of epinephrine is 
not recommended.39–41
Advanced Options
In patients with pre-capillary pulmonary hypertension, therapy should 
be driven by treatment of the underlying disease. Long-term oxygen 
therapy in hypoxic patients might stabilise pulmonary hypertension 
despite continued progression of lung disease, whereas supplementary 
oxygen in patients without hypoxia or moderate desaturation is not 
beneficial.42,43 The role of pulmonary vasodilators is highly controversial. 
Intravenous prostacyclin analogues effectively reduce RV afterload, but 
may aggravate systemic hypotension. Alternatively, inhaled nitric oxide 
or inhaled prostacyclin may be considered.33 These agents should be 
used only in an appropriate setting (specialised units) and in selected 
patients because of the risk of an increase in ventilation/perfusion 
mismatch and subsequent clinical deterioration. Notably, long-term 
therapy with phosphodiesterase-5 inhibitors, endothelin receptor 
antagonists, guanylate cyclase stimulators, prostacyclin analogues and 
prostacyclin receptor agonists are not recommended for the treatment 
of pulmonary hypertension due to left heart disease, which is the most 
prevalent cause of RV dysfunction.
In patients with refractory RV failure despite treatment with 
vasopressors and inotropes, advanced therapeutic options including 
fibrinolysis for pulmonary embolism or mechanical circulatory support 
should be considered (see below). 
In the absence of long-term therapeutic options, palliation and 
supportive care should be offered to patients and relatives.44
Mechanical Circulatory Support for Advanced 
Right Ventricular Failure
Mechanical circulatory support with RV assist devices (RVADs) should 
be considered when RV failure persists despite treatment with 
vasopressors and inotropes (Figure 3). Because reversibility of severe 
RV failure is more likely to be possible and more rapid than LV failure 
of similar magnitudes, temporary RVADs (t-RVADs) can be a valuable 
therapeutic option for many patients.45 The often-reported poor 
survival rates of RVAD recipients should not discourage the appropriate 
use of t-RVADs, because patient mortality depends mainly on the 
primary cause of RV failure, the severity of end-organ dysfunction and 
the timing of RVAD implantation, and much less on adverse events 
and complications related to RVAD implantation, mechanical support 
or removal (selection bias).12 The most important determinants of 
success are optimal patient selection (according to age, comorbidities, 
RV dysfunction aetiology and reversibility potential) and optimal timing 
of implantation to avoid significant, potentially irreversible end-organ 
injury. For that reason, these patients require close haemodynamic 
and laboratory monitoring, with particular attention to liver and kidney 
function, and early transfer to a centre with experience in RVAD 
implantation in case of persistent haemodynamic instability. 
Choosing the most appropriate device also maximises the success 
of mechanical circulatory support. First, the strategy (e.g. bridge to 
recovery, bridge to bridge – i.e. LVAD/biventricular VAD/total artificial 
heart – or bridge to transplant) should be defined. Second, the need 
for an oxygenator should be anticipated because it may influence 
device selection. Third, the function of both the LV and RV should 
be carefully assessed to predict the need for isolated RV support 
or biventricular support (either durable or temporary). In addition 
to device characteristics, it is crucial to consider local expertise 
and availability. 
For short-term support, several t-RVADs, both percutaneous and 
surgical devices, are available.
Percutaneous t-RVADs allow early initiation of support without the 
need for surgery. They are approved for a shorter period of time, and 
can sustain a lower flow than surgical devices. They are categorised 
according to their mechanism of action as either ‘direct RV bypass’, 
such as the Impella RP (Abiomed) and TandemHeart RVADs (TandemLife) 
or ‘indirect RV bypass’ systems, such as venous-arterial ECMO (VA 
ECMO).46 Impella RP is a microaxial flow 22 Fr catheter, approved for 
14 days’ use, that delivers blood (at a rate of up to 4 l/min) from the 
RA into the pulmonary artery (PA).47 The TandemHeart RVAD uses an 
extracorporeal centrifugal flow pump and two venous cannulas or a 
single cannula with two lumens (Protek Duo cannula) to deliver blood 
from the RA to the PA with the additional possibility of oxygenating 
the blood.48 Directly bypassing the RV function reduces RA pressure, 
raises mean PA pressure and increases left ventricular preload, while 
the left ventricular afterload remains unchanged. The VA ECMO is 
the less expensive device. It bypasses the RV indirectly, displacing 
venous blood from the RA across an oxygenator into the peripheral 
arterial circulation. It induces a decrease in RA and PA pressure and 
LV preload but increases LV afterload if not cannulated centrally via 
surgical access.49 
Surgical t-RVADs require an open sternotomy or thoracotomy for direct 
RA and PA cannulation and their connection to an extracorporeal 
centrifugal flow pump. They allow more extended and greater support 
in terms of flow at the cost of an invasive implantation and removal. 
However, more recently developed surgically implantable short-term 
extracorporeal CF-RVADs can be removed without reoperation; that 
is, the CentriMag system (Chalice Medical), which allows 30 days of 
support with up to 10 l/min blood flow).50 
For more durable, long-term support, isolated pulsatile RVADs, 
surgically deployed rotary-flow RVADs and biventricular support 
with pulsatile VADs or total artificial heart replacement are potential 
options; however, the majority of patients using these are required to 
remain in the hospital under close surveillance. This is one reason why 
the use of durable isolated right ventricular assist devices (e.g. LVADs in 
the RV position) to support isolated RV or biventricular failure has been 
evaluated.51–54 A significant limitation of this approach is that LVADs are 
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designed to operate in the systemic circulation with higher resistance 
and, where pulmonary resistance is low, they are more prone to 
complications, such as repetitive suction events. Because of the many 
technical limitations of durable RV support and because RV function 
may not recover, cardiac transplantation remains the only successful 
long-term treatment.
Arrhythmic Aspects of Right Ventricular Failure 
Cardiac rhythm plays an important yet often underestimated role in 
RV function. One one hand, the failing RV, specifically if experiencing 
an increased afterload, such as in pulmonary hypertension, is highly 
dependent on a regular heart rate to function adequately, as its 
contractile reserve is very limited.55 The need for a constant sympathetic 
drive to maintain cardiac output may be one reason why beta-blocker 
therapy is not effective in right heart failure.56 
On the other hand, RV pressure overload, an integral part in the 
pathophysiology of RV failure, is often associated with supraventricular 
arrhythmias, such as atrial fibrillation, atrial flutter or (multi-)focal 
atrial tachycardia, all of which negatively affect RV filling and thereby 
contribute to the vicious cycle of aggravating RV failure, eventually 
culminating in cardiogenic shock. Therefore, in addition to careful 
volume management to optimise RV preload and RV wall stress, 
prompt rhythm control of supraventricular tachyarrhythmias is central. 
Importantly, diastolic filling of the failing RV depends on atrial 
contraction (‘atrial kick’) and atrioventricular synchrony.57,58 Therefore, 
rate control alone is generally insufficient to restore haemodynamic 
stability.59 In the acute setting, prompt electrical cardioversion (ECV) is 
the treatment of choice to restore sinus rhythm, although ECV efficacy 
in restoring and maintaining sinus rhythm may be reduced in critically 
ill patients.58,60,61
Retrospective analyses in patients with pulmonary hypertension 
indicate that maintaining sinus rhythm is associated with a reduction 
in clinical deterioration.62 Since beta-blockers and calcium channel 
antagonists may hamper RV contractility because of their negative 
inotropic effect, amiodarone should be used if antiarrhythmic medical 
therapy to maintain sinus rhythm is warranted. Class Ic antiarrhythmics, 
as well as sotalol and dronedarone, should not be used in structural 
heart disease. If medical therapy fails, AV synchronous pacing, with 
either the patient’s indwelling device or transvenous pacing wires may 
be considered.2
The interplay of the right and left ventricles, sharing their interventricular 
septum and competing for the limited space within the pericardium, 
leads to ventricular interdependence.33 Consequently, the loss of 
synchronous ventricular contraction is associated with a significant 
deterioration of RV contractile force. Notably, cardiac resynchronisation 
therapy (CRT) is standard care in patients with heart failure with 
reduced LV ejection fraction (HFrEF) and a wide QRS complex 
(>130 ms), and serves to resynchronise LV contraction. Many patients 
with HFrEF also have reduced RV function, either as a consequence 
of increased RV afterload (post-capillary pulmonary hypertension) or 
secondary to a cardiomyopathy affecting both ventricles.33
Because of anatomical and technical obstacles (difficult reliable 
assessment of RV function and the absence of an epicardial RV 
venous system for safe lead placement) and as RV function has gained 
attention only in recent years, very limited data on isolated right 
cardiac resynchronisation exist. However, though scarce, there are 
data on the interplay of LV resynchronisation and RV function. Indeed, 
reverse LV remodelling is associated with reduced RV afterload.63 
Not surprisingly, several observational studies have demonstrated 
significant improvement in RV function after CRT.64 Similarly, CRT was 
associated with significant improvement of RV fractional area change 
in a post-hoc analysis of the Multicenter Automatic Defibrillator 
Implantation Trial With Cardiac Resynchronization Therapy trial (MADIT-
CRT).65 However, no such effect was observed in a post-hoc analyses 
of the REsyncronization reVErses Remodeling in Systolic left vEntricular 
dysfunction (REVERSE) and Cardiac Resynchronization-Heart Failure 
(CARE-HF) trials, which used TAPSE to assess RV function.66,67 Of note, 
TAPSE is mainly influenced by longitudinal movement of the RV free 
wall and may underestimate the contribution of the interventricular 
septum and outflow tract. Importantly, both observational studies 
and post-hoc analyses of randomised clinical trials may serve only to 
generate hypotheses and do not allow reliable conclusions. The value 
of left cardiac resynchronisation in isolated RV failure is unknown. 
Similarly, data on the prevalence of sudden cardiac death (SCD) in 
isolated RV failure are scarce, at best. It is therefore not surprising 
that current guidelines do not recommend ICD therapy for primary 
prevention of SCD in patients with isolated RV failure.68 An exemption 
is patients with arrhythmogenic RV cardiomyopathy, in whom, if certain 
risk factors for SCD are present, an ICD for primary prevention of SCD 
may be considered (IIb; level of evidence C). In cases of secondary 
prevention, on the other hand, after documented haemodynamically 
relevant ventricular tachycardia or following survived SCD, and after 
secondary causes have been excluded, ICD therapy is recommended, 
regardless of right or left ventricular function.
Conclusion
The assessment of RV failure should consider the anatomical and 
physiological particularities of the RV and include appropriate 
imaging techniques to understand the underlying pathophysiological 
mechanisms. 
Treatment should include rapid optimisation of volume status, 
restoration of perfusion pressure, and improvement of myocardial 
contractility and rhythm and, in case of refractory RV failure, mechanical 
circulatory support. 
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